Disappointing findings from recent phase III trials on amyloid-β (Aβ) immunotherapy for Alzheimer's disease (AD) have shifted the focus of such treatments to the tau protein. As tau pathology correlates better with the degree of dementia than Aβ plaque burden, it is a more attractive target once cognitive impairments are evident, while Aβ therapies may be better suited for the presymptomatic phase of the disease. Over 12 years ago, we initiated a tau immunotherapy program, seeking to alleviate the functional impairments associated with tau lesions in tauopathies. We have reported that various active and passive tau immunizations diminish tau pathology and improve function, including cognition, in different mouse models. Both extra- and intracellular pathways are likely involved. The antibodies may block the spread of tau pathology via microglial phagocytosis of the antibody-tau complex and facilitate lysosomal tau clearance in neurons after endosomal uptake. We have observed such antibody internalization following intracarotid injection in mice and in various culture models. These include brain slices and primary neurons from tangle mice as well as human neuroblastoma cell lines. Antibody targeting of different intracellular protein aggregates, including α-synuclein, Aβ and superoxide dismutase has been reported by others. Now, several laboratories have confirmed and extended our findings using various active and passive tau immunizations in different models, thereby clearly establishing the feasibility of this approach for clinical trials. We are also working on imaging approaches to monitor tau pathology, its consequences and the efficacy of treatments. Dire need exists for such diagnostic methods for tauopathies. Overall, therapies and diagnostic tools targeting tau pathology have a great potential for AD and other tauopathies.

Keywords:
Alzheimer’s disease, Tauopathies, Tau, Neurofibrillary tangles, Immunotherapy, Immunization, Vaccine
1.
Aisen PS, Vellas B: Editorial: passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed? J Nutr Health Aging 2013;17:49-50.
2.
Gu J, Sigurdsson EM: Immunotherapy for tauopathies. J Mol Neurosci 2011;45:690-695.
3.
Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007;27:9115-9129.
4.
Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010;30:16559-16566.
5.
Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM: Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011;118:658-667.
6.
Boutajangout A, Rajamohamed Sait HB, Gonzalez V, Sigurdsson EM: Targeting hyperphosphorylated tau protein with a monoclonal antibody at an advanced stage of tau pathology improves cognition in a mouse model. Alzheimers Dement 2011;7(suppl 4):S480-S481.
7.
Krishnamurthy PK, Deng Y, Sigurdsson EM: Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front Psychiatry 2011;2:59.
8.
Gu J, Sigurdsson EM: Efficacy and mechanisms of antibody-mediated clearance of tau aggregates in brain slice model. Soc Neurosci Meeting Abstract 852.12, New Orleans, 2012.
9.
Congdon E, Sait H, Boutajangout A, Sigurdsson EM: Tau antibody uptake into neurons strongly correlates with degree of tau pathology and is primarily receptor-mediated via low affinity Fcgamma receptors. Soc Neurosci Meeting Abstract 852.10, New Orleans, 2012.
10.
Clavaguera F, Lavenir I, Falcon B, Frank S, Goedert M, Tolnay M: ‘Prion-like' templated misfolding in tauopathies. Brain Pathol 2013;23:342-349.
11.
Walker LC, Diamond MI, Duff KE, Hyman BT: Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 2013;70:304-310.
12.
Valera E, Masliah E: Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies. Pharmacol Ther 2013;138:311-322.
13.
Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H: Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010;224:472-485.
14.
Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M: Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 2011;286:34457-34467.
15.
Bi M, Ittner A, Ke YD, Gotz J, Ittner LM: Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011;6:e26860.
16.
Troquier L, Caillierez M, Burnouf S, Fernandez-Gomez FJ, Grosjean MJ, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L: Targeting phospho-Ser422 by active tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 2012;9:397-405.
17.
Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI: Trans-cellular propagation of tau aggregation by fibrillar species. J Biol Chem 2012;287:19440-19451.
18.
d'Abramo C, Acker CM, Jimenez HT, Davies P: Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 2013;8:e62402.
19.
Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O: Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006;63:1459-1467.
20.
Shin J, Kepe V, Barrio JR, Small GW: The merits of FDDNP-PET imaging in Alzheimer's disease. J Alzheimers Dis 2011;26(suppl 3):135-145.
21.
Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O'Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL: 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011;134:1089-1100.
22.
Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Szardenings AK, Wang E, Walsh JC, Xia C, Yu C, Zhao T, Kolb HC: A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis 2012;31:601-612.
23.
Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC: Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013;34:457-468.
25.
Lin YJ, Koretsky AP: Manganese ion enhances T1-weighted MRI during brain activation: an approach to direct imaging of brain function. Magn Reson Med 1997;38:378-388.
26.
Koretsky AP: Is there a path beyond BOLD? Molecular imaging of brain function. Neuroimage 2012;62:1208-1215.
27.
Watanabe T, Natt O, Boretius S, Frahm J, Michaelis T: In vivo 3D MRI staining of mouse brain after subcutaneous application of MnCl2. Magn Reson Med 2002;48:852-859.
28.
Wadghiri YZ, Blind JA, Duan XH, Moreno C, Yu X, Joyner AL, Turnbull DH: Manganese-enhanced magnetic resonance imaging (MEMRI) of mouse brain development. NMR Biomed 2004;17:613-619.
29.
Bertrand A, Khan U, Hoang DM, Novikov DS, Krishnamurthy P, Rajamohamed Sait HB, Little BW, Sigurdsson EM, Wadghiri YZ: Non-invasive, in vivo monitoring of neuronal transport impairment in a mouse model of tauopathy using MEMRI. Neuroimage 2013;64:693-702.
30.
Little BW, Khan U, Rajamohamed Sait H, Hoang DM, Bertrand A, Wadghiri YZ, Sigurdsson EM: Tau immunotherapy improves axonal transport as detected in vivo by manganese-enhanced magnetic resonance imaging. Alzheimers Dement 2012; 8:38.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.